

Yoshie Umemura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1023075/publications.pdf>

Version: 2024-02-01

36
papers

536
citations

840776

11
h-index

677142

22
g-index

36
all docs

36
docs citations

36
times ranked

961
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic susceptibility contrast and diffusion-weighted MRI in posterior fossa pilocytic astrocytoma and medulloblastoma. <i>Journal of Neuroimaging</i> , 2022, , .	2.0	2
2	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	1.2	38
3	DDRE-28. MECHANISTIC AND THERAPEUTIC LINKS BETWEEN PURINE BIOSYNTHESIS AND DNA DAMAGE IN GLIOBLASTOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i12-i12.	0.7	0
4	DDRE-19. PHASE 0/I TRIAL OF MYCOPHENOLATE MOFETIL COMBINED WITH RADIATION TO OVERCOME GLIOBLASTOMA TREATMENT RESISTANCE BY TARGETING DE-NOVO PURINE METABOLISM. <i>Neuro-Oncology Advances</i> , 2021, 3, i10-i10.	0.7	0
5	DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE. <i>Neuro-Oncology Advances</i> , 2021, 3, i11-i11.	0.7	1
6	Abstract PO-008: Mechanistic and therapeutic links between purine biosynthesis and DNA damage in glioblastoma. , 2021, , .		0
7	A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 792-803.	0.8	23
8	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 703764.	2.8	27
9	Pharmacoresistant seizures and IDH mutation in low-grade gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab146.	0.7	5
10	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. <i>Journal of Neuro-Oncology</i> , 2020, 146, 339-346.	2.9	17
11	Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. <i>Nature Communications</i> , 2020, 11, 3811.	12.8	103
12	Tolerability of radiation with concurrent temozolomide and effect on survival in chemo-refractory CNS lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14554-e14554.	1.6	0
13	Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3615-3615.	1.6	8
14	Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3617-3617.	1.6	2
15	Abstract CT105: First in human phase I trial of adenoviral vectors expressing Flt3L and HSV1-TK to treat newly diagnosed high-grade glioma by reprogramming the brain immune system. , 2020, , .		1
16	Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response. <i>Blood</i> , 2020, 136, 12-12.	1.4	1
17	CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii50-ii51.	1.2	1
18	NCMP-03. INTRATHECAL TRASTUZUMAB TREATMENT OF HER-2 POSITIVE LEPTOMENINGEAL BREAST CANCER: THE UNIVERSITY OF MICHIGAN EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, ii123-ii123.	1.2	1

#	ARTICLE	IF	CITATIONS
19	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii45-ii46.	1.2	0
20	EPID-27. THE VANISHING TUMOR PHENOMENON IN THE DIAGNOSIS OF PRIMARY CNS LYMPHOMA. <i>Neuro-Oncology</i> , 2020, 22, ii84-ii84.	1.2	1
21	First in Human Phase I Trial of Dual Vector (HSV1-TK, Flt3L) Immunotherapy For The Treatment of Newly Diagnosed High-Grade Glioma: Initial Results. <i>Neurosurgery</i> , 2019, 66, 310-152.	1.1	0
22	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. <i>Journal of Neuro-Oncology</i> , 2019, 145, 97-105.	2.9	125
23	Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 313-319.	2.9	11
24	ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi20-vi21.	1.2	1
25	ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM. <i>Neuro-Oncology</i> , 2019, 21, vi11-vi11.	1.2	4
26	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi186-vi186.	1.2	2
27	RTHP-34. IMPROVED SURVIVAL IN CNS LYMPHOMA WITH SALVAGE LOW-DOSE WHOLE-BRAIN RADIOTHERAPY WITH FOCAL BOOST AND CONCURRENT TEMOZOLOMIDE. <i>Neuro-Oncology</i> , 2019, 21, vi217-vi217.	1.2	0
28	HOUT-08. PATIENT AND PHYSICIAN PERSPECTIVES ON LUMBAR PUNCTURE. <i>Neuro-Oncology</i> , 2019, 21, vi113-vi113.	1.2	0
29	First-in-human phase I trial of the combination of two adenoviral vectors expressing HSV1-TK and FLT3L for the treatment of newly diagnosed resectable malignant glioma: Initial results from the therapeutic reprogramming of the brain immune system.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2019-2019.	1.6	15
30	Bevacizumab and Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 180-186.	2.0	78
31	The Utility of Liquid Biopsy in Central Nervous System Malignancies. <i>Current Oncology Reports</i> , 2018, 20, 60.	4.0	29
32	NTOX-15. PATIENT PERSPECTIVES ON LUMBAR PUNCTURE. <i>Neuro-Oncology</i> , 2017, 19, vi168-vi168.	1.2	0
33	BMET-12. IS CISTERNAL PUNCTURE UNDERUTILIZED?. <i>Neuro-Oncology</i> , 2016, 18, vi28-vi28.	1.2	0
34	Fatal 251-NBOMe Intoxication: A New Recreational Risk. <i>Academic Forensic Pathology</i> , 2015, 5, 91-97.	0.3	5
35	Mu α opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic α pituitary α adrenal axis adrenocorticotrophic hormone stress response to metyrapone. <i>Addiction Biology</i> , 2013, 18, 325-331.	2.6	34
36	Efficacy and Toxicity with Radiation Field Designs and Concurrent Temozolomide for CNS Lymphoma. <i>Neuro-Oncology Practice</i> , 0, , .	1.6	1